Safia Khalil Rizvi

Dr. Rizvi brings over 20 years of experience in all aspects of Biopharma value chain, from drug discovery to commercialization. She Leverages science and business expertise to enhance pipeline, accelerate regulatory approval, optimize reimbursement, and creates value for biopharma. Over the 20 years, she closed deals worth a combined total of $12+ billion, managed P&L of > $1 billion, and launched 10 products in the US, EU, and Asia Pacific, each with different regulatory and market access environments.

Dr. Rizvi is also a founder Cila Therapeutics, a company developing inhaled therapeutics for respiratory rare diseases. While there, she translated scientific concepts into a robust pipeline of 5 programs and built a team of advisors with world class experts in pulmonary medicine, inhaled therapeutics and biopharma R&D.

Prior to Cila Therapeutics, she was the Managing Director of The Blue Group, a strategic advisory company for biopharma companies for portfolio, partnership, product development and commercialization of therapeutic products.